Cisplatin

• 

  Subject Areas on Research

  • 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. 
  • A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. 
  • A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. 
  • A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. 
  • A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? 
  • A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. 
  • A genomic approach to identify molecular pathways associated with chemotherapy resistance. 
  • A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. 
  • A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. 
  • A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. 
  • A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 
  • A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. 
  • A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy. 
  • A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. 
  • A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. 
  • A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. 
  • A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. 
  • A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer. 
  • A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. 
  • A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. 
  • A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. 
  • A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. 
  • A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. 
  • A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). 
  • A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. 
  • A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. 
  • A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. 
  • A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. 
  • A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. 
  • A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment. 
  • A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. 
  • ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. 
  • ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy. 
  • Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. 
  • Absence of whole body hyperthermia effect on cisplatin distribution in spontaneous canine tumors. 
  • Active chemotherapy for metastatic stromal cell tumor of the testis. 
  • Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. 
  • Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. 
  • Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. 
  • Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. 
  • Altered clearance of human alpha 2-macroglobulin complexes following reaction with cis-dichlorodiamineplatinum(II). 
  • Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. 
  • Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636. 
  • Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. 
  • An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. 
  • An integrative approach identified genes associated with drug response in gastric cancer. 
  • Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. 
  • Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. 
  • Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs. 
  • Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer. 
  • Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. 
  • Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. 
  • Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck. 
  • Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. 
  • Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. 
  • Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. 
  • BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. 
  • Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? 
  • Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. 
  • Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. 
  • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. 
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. 
  • Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. 
  • Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. 
  • Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis. 
  • Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience. 
  • Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). 
  • Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. 
  • Chemotherapy-Induced Depletion of OCT4-Positive Cancer Stem Cells in a Mouse Model of Malignant Testicular Cancer. 
  • Chemotherapy-induced apoptosis in epithelial ovarian cancers. 
  • Childhood hepatic mesenchymoma: successful treatment with surgery and multiple-agent chemotherapy. 
  • Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. 
  • Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. 
  • Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. 
  • Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro. 
  • Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. 
  • Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. 
  • Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. 
  • Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. 
  • Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. 
  • Cisplatin-induced changes in sodium, chloride, and urea transport by the frog skin. 
  • Cisplatinum-induced renal salt wasting. 
  • Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. 
  • Cloning efficiency of cultured human tumor cell lines measured with the use of a Coulter particle counter. 
  • Clostridium septicum abscess in hepatic metastases: successful medical management. 
  • Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. 
  • Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. 
  • Combined treatment approaches in regionally advanced bladder cancer. 
  • Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer. 
  • Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. 
  • Competing Actions of Type 1 Angiotensin II Receptors Expressed on T Lymphocytes and Kidney Epithelium during Cisplatin-Induced AKI. 
  • Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. 
  • Complexes of serum albumin and cis-dichlorodiammineplatinum (II). The role of cysteine 34 as a nucleophilic entering group and evidence for reaction between bound platinum and a second macromolecule. 
  • Complications of therapy for testicular cancer. 
  • Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. 
  • Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. 
  • Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. 
  • Correlation of intralesional in vivo chemotherapy of line 10 hepatoma with in vitro drug sensitivity. 
  • Correlation of total and interstrand DNA adducts in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin. 
  • Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. 
  • Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. 
  • Cyclocreatine in cancer chemotherapy. 
  • Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase. 
  • Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions. 
  • Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. 
  • DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. 
  • DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. 
  • DNA interstrand crosslinking and strand break repair in human glioma cell lines of varying [1,3-bis(2-chloroethyl)-1-nitrosourea] resistance. 
  • Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. 
  • Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells. 
  • Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 
  • Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. 
  • Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. 
  • Does vocal cord fixation preclude nonsurgical management of laryngeal cancer? 
  • Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer. 
  • Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma. 
  • Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. 
  • Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. 
  • Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. 
  • Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. 
  • Dynamic contrast-enhanced MRI promotes early detection of toxin-induced acute kidney injury. 
  • Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. 
  • Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. 
  • Effect of DNA conformation on cisplatin adduct formation. 
  • Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro. 
  • Effect of hyperthermia on cisplatin pharmacokinetics in normal dogs. 
  • Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. 
  • Effects of diethyldithiocarbamate and nine other nucleophiles on the intersubunit protein cross-linking and inactivation of purified human alpha 2-macroglobulin by cis-diamminedichloroplatinum(II). 
  • Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. 
  • Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. 
  • Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. 
  • Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. 
  • Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. 
  • Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. 
  • Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. 
  • Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. 
  • Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice. 
  • Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. 
  • Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. 
  • Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. 
  • Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. 
  • Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. 
  • Evidence that the platinum-reactive methionyl residue of the alpha 2-macroglobulin receptor recognition site is not in the carboxyl-terminal receptor binding domain. 
  • Evolution and Management of Treatment-Related Toxicity in Anal Cancer. 
  • Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. 
  • Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. 
  • FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. 
  • Fanconi's anemia in adulthood: chemoradiation-induced bone marrow failure and a novel FANCA mutation identified by targeted deep sequencing. 
  • Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. 
  • Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. 
  • Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. 
  • Five hundred patients with Merkel cell carcinoma evaluated at a single institution. 
  • Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. 
  • Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. 
  • Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells. 
  • Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease. 
  • Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. 
  • Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta. 
  • Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes. 
  • Further characterization of the platinum-reactive component of the alpha 2-macroglobulin-receptor recognition site. 
  • Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. 
  • Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer. 
  • Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. 
  • Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. 
  • Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. 
  • Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. 
  • HPV16-associated squamous cell carcinoma of the tongue metastatic to the ciliary body, iris, and lacrimal gland. 
  • Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. 
  • High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. 
  • High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. 
  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. 
  • High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. 
  • High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. 
  • High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. 
  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. 
  • High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. 
  • High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. 
  • High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). 
  • Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. 
  • Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. 
  • Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139). 
  • Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. 
  • Hypoxia impedes the formation of chromium DNA-adducts in a cell-free system. 
  • Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. 
  • Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. 
  • Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 
  • Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. 
  • Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. 
  • In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. 
  • In vitro chemotherapy testing of transitional cell carcinoma. 
  • In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. 
  • In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. 
  • Inactivation of the plasma protease inhibitor alpha 2-macroglobulin by the antitumor drug cis-dichlorodiamineplatinum(II). 
  • Independent analysis of bait region cleavage dependent and thiolester bond cleavage dependent conformational changes by cross-linking of alpha 2-macroglobulin with cis-dichlorodiammineplatinum(II) and dithiobis(succinimidyl propionate). 
  • Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. 
  • Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). 
  • Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: experience with Cisplatinum-based chemoradiotherapy in 76 patients. 
  • Initial testing of cisplatin by the pediatric preclinical testing program. 
  • Intensity-modulated radiation therapy for anal cancer. 
  • Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. 
  • Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. 
  • Interlaboratory validation of a new assay for DNA-protein crosslinks. 
  • Interleukin 1 receptor (IL-1R1) activation exacerbates toxin-induced acute kidney injury. 
  • Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. 
  • Intersubunit cross-linking by cis-dichlorodiammineplatinum(II) stabilizes an alpha 2-macroglobulin "nascent" state: evidence that thiol ester bond cleavage correlates with receptor recognition site exposure. 
  • Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. 
  • Intra-arterial cisplatinum in preparation for the limb salvage procedure. 
  • Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. 
  • Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum. 
  • Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. 
  • Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. 
  • Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. 
  • Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. 
  • Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer. 
  • Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Leiomyosarcoma in childhood and adolescence. 
  • Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. 
  • Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. 
  • Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. 
  • Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. 
  • Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. 
  • Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells. 
  • MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. 
  • Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. 
  • Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. 
  • Management of pineal non-germinoma germ cell tumor with residual teratoma and normal alpha-fetoprotein. 
  • Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. 
  • Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. 
  • Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. 
  • MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. 
  • Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. 
  • Modification of the tandem reactive centres of human inter-alpha-trypsin inhibitor with butanedione and cis-dichlorodiammineplatinum(II). 
  • Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. 
  • Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. 
  • Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. 
  • Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. 
  • Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. 
  • Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. 
  • Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. 
  • Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. 
  • Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. 
  • Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier. 
  • Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. 
  • Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. 
  • Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. 
  • Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. 
  • Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • Nonuniform alteration of cis-diamminedichloroplatinum(II) tissue distribution in dogs with whole body hyperthermia. 
  • Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. 
  • Ocular toxicity following high dose chemotherapy and autologous transplant. 
  • Oral ondansetron pharmacokinetics: the effect of chemotherapy. 
  • Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. 
  • PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. 
  • Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. 
  • Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. 
  • Pancreatoblastoma in a teenage patient. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. 
  • Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro. 
  • Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. 
  • Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. 
  • Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. 
  • Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. 
  • Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer. 
  • Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid. 
  • Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies. 
  • Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. 
  • Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. 
  • Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). 
  • Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group Trial. 
  • Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. 
  • Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. 
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). 
  • Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. 
  • Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. 
  • Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. 
  • Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. 
  • Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. 
  • Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. 
  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. 
  • Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. 
  • Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. 
  • Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. 
  • Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. 
  • Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. 
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. 
  • Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). 
  • Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. 
  • Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. 
  • Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. 
  • Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. 
  • Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. 
  • Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. 
  • Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. 
  • Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. 
  • Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. 
  • Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report. 
  • Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. 
  • Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study. 
  • Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. 
  • Primary chemotherapy in epithelial ovarian cancer. 
  • Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. 
  • Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. 
  • Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. 
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. 
  • REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks. 
  • Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. 
  • Radiotherapy in pediatric medulloblastoma: quality assessment of Pediatric Oncology Group Trial 9031. 
  • Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. 
  • Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. 
  • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. 
  • Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). 
  • Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. 
  • Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. 
  • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. 
  • Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. 
  • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. 
  • Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. 
  • Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. 
  • Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. 
  • Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. 
  • Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts. 
  • Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. 
  • Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. 
  • Reply to L. Fornaro et al. 
  • Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. 
  • Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. 
  • Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. 
  • Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. 
  • Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. 
  • Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. 
  • Role of angiotensin II and vasopressin in cisplatin-induced emesis. 
  • Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. 
  • Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins. 
  • Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer. 
  • Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. 
  • Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. 
  • Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. 
  • Sickness behavior clustering in children with cancer. 
  • Significant responses to platinum-based chemotherapy in renal medullary carcinoma. 
  • Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin. 
  • Successful treatment of mediastinal germ cell/endodermal sinus tumors. 
  • Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. 
  • Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. 
  • Systemic chemotherapy for urothelial cancer. 
  • Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma. 
  • TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. 
  • TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). 
  • Temporal lobe injury patterns following intensity modulated radiotherapy in a large cohort of nasopharyngeal carcinoma patients. 
  • Testicular cancer in blacks. A multicenter experience. 
  • The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. 
  • The DNA helicase activities of Rad3 protein of Saccharomyces cerevisiae and helicase II of Escherichia coli are differentially inhibited by covalent and noncovalent DNA modifications. 
  • The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis. 
  • The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. 
  • The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination. 
  • The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. 
  • The other function of DNA photolyase: stimulation of excision repair of chemical damage to DNA. 
  • The p35 relative, p49, inhibits mammalian and Drosophila caspases including DRONC and protects against apoptosis. 
  • The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. 
  • The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. 
  • The role of optimal debulking in advanced stage serous carcinoma of the uterus. 
  • The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer. 
  • Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. 
  • Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. 
  • Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide. 
  • Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. 
  • Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. 
  • Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. 
  • Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. 
  • Trypanosoma brucei gambiense: growth in vitro of bloodstream forms inhibited by dichlorodiammineplatinum (II) compounds and hypolipidemic drugs. 
  • Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin. 
  • Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. 
  • US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. 
  • Unnecessary mastectomy for gynecomastia in testicular cancer patient. 
  • Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha 2-macroglobulin receptor recognition site. 
  • Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. 
  • Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. 
  • Weekly administration of cis-dichlorodiammineplatinum(II) in childhood solid tumors: a Southwest Oncology Group study. 
  • Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. 
  • White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. 
  • White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. 
  • Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? 
  • X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. 
  • Yin yang 1 modulates taxane response in epithelial ovarian cancer. 
  • cis-dichlorodiammineplatinum (II) as a selective modifier of the oxidation-sensitive reactive-center methionine in alpha 1-antitrypsin. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Distinguished Professor of Medical Oncology, Medicine, Medical Oncology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering